Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn’s Disease Patients: A Case Report and Review of the Literature

Recently, ustekinumab has been approved for the treatment of Crohn’s disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present details of three patients with therapy-refractory Crohn’s disease who experienced an immediate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Pepijn W A, Ferwerda, Gerben, West, Rachel L, Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805788/
https://www.ncbi.nlm.nih.gov/pubmed/32588044
http://dx.doi.org/10.1093/ecco-jcc/jjaa115
Descripción
Sumario:Recently, ustekinumab has been approved for the treatment of Crohn’s disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present details of three patients with therapy-refractory Crohn’s disease who experienced an immediate infusion reaction to intravenous administration of ustekinumab. In two of these patients a subsequent reaction to subcutaneous injections occurred. Clinical features and pathophysiology are discussed.

Ejemplares similares